Antidepressant-induced Paradoxical Anxiety, Akathisia, and Complex Vocal Tics in a Patient with Panic Disorder and Crohn’s Disease: A Case Report

Page: [478 - 481] Pages: 4

  • * (Excluding Mailing and Handling)

Abstract

Background: Antidepressant-induced paradoxical anxiety is a fairly common phenomenon seen in patients who are initiated on antidepressants. However, akathisia is a very uncommon manifestation of antidepressants. Much more rarely, antidepressants are also associated with the emergence of motor and vocal tics. This case adds to the growing literature of rare adverse events induced by antidepressants and aims to stimulate future research into the mechanism and risk factors of this phenomenon.

Case Presentation: In this case report, we describe a patient with panic disorder and co-morbid Crohn’s disease who developed worsening anxiety, akathisia and vocal tics upon initiation of fluvoxamine. This is the first case report to describe the emergence of both akathisia and vocal tics in the same patient following antidepressant initiation. After discontinuation of fluvoxamine, the patient’s symptoms resolved.

Conclusion: Antidepressant-induced akathisia and tics are often distressing both to the patient and their loved ones, and can be very puzzling to the clinician. It is important for clinicians to recognise that, although rare, antidepressants can adverse effects. When these symptoms arise, it should prompt immediate discontinuation of the offending antidepressant.

[1]
Sinclair LI, Christmas DM, Hood SD, et al. Antidepressant-induced jitteriness/anxiety syndrome: Systematic review. Br J Psychiatry 2009; 194(6): 483-90.
[http://dx.doi.org/10.1192/bjp.bp.107.048371] [PMID: 19478285]
[2]
Reinblatt SP, dosReis S, Walkup JT, Riddle MA. Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents. J Child Adolesc Psychopharmacol 2009; 19(2): 119-26.
[http://dx.doi.org/10.1089/cap.2008.040] [PMID: 19364290]
[3]
Li Z, Pfeiffer PN, Hoggatt KJ, et al. Emergent anxiety after antidepressant initiation: a retrospective cohort study of Veterans Affairs Health System patients with depression. Clin Ther 2011; 33(12): 1985-1992.e1.
[http://dx.doi.org/10.1016/j.clinthera.2011.11.010] [PMID: 22177372]
[4]
Harada T, Sakamoto K, Inada K, Yamada K, Ishigooka J. A prospective naturalistic study of antidepressant-induced jitteriness/anxiety syndrome. Neuropsychiatr Dis Treat 2014; 10: 2115-21. http://www.dovepress.com/getfile.php?fileID=22361%5Cn http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed12&NEWS=N&AN=2014894374
[http://dx.doi.org/10.2147/NDT.S70637] [PMID: 25419134]
[5]
Sinha P, Shetty DJ, Bairy LK, Andrade C. Antidepressant-related jitteriness syndrome in anxiety and depressive disorders: Incidence and risk factors. Asian J Psychiatr 2017; 29: 148-53.
[http://dx.doi.org/10.1016/j.ajp.2017.06.003] [PMID: 29061415]
[6]
NICE. Generalised anxiety disorder and panic disorder in adults: management. Natl Inst Heal Clin Excell 2020; 20. Available from: www.nice.org.uk/guidance/cg113%0A https://www.nice.org.uk/guidance/cg113/chapter/1-Guidance
[7]
David M. The Maudsley Prescribing Guidelines in Psychiatry. (14th Edition.), Wiley Blackwel 2021.
[8]
Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part I: Anxiety disorders. World J Biol Psychiatry 2023; 24(2): 79-117.
[http://dx.doi.org/10.1080/15622975.2022.2086295] [PMID: 35900161]
[9]
Food and Drug Administration. Worsening depression and suicidality in patients being treated with antidepressant [Internet]. FDA Public Health Advisory 2004. Available from: http://www.fda.gov/CDER/DRUG/antidepressants/AntidepressanstPHA.htm
[10]
Yeragani VK, Pohl R, Baton R, Ramesh C, Weinberg P. Imipramine-induced jitteriness and decreased serum iron levels. Neuropsychobiology 1992; 25(1): 8-10.
[http://dx.doi.org/10.1159/000118801] [PMID: 1603294]
[11]
Ramos RT, Gentil V, Gorenstein C. Clomipramine and initial worsening in panic disorder: beyond the ‘jitteriness syndrome’. J Psychopharmacol 1993; 7(3): 265-9.
[http://dx.doi.org/10.1177/026988119300700305] [PMID: 22290840]
[12]
Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry 2004; 65(7): 959-65.
[http://dx.doi.org/10.4088/JCP.v65n0712] [PMID: 15291685]
[13]
Ajufo I, Basiru TO. Akathisia as an extrapyramidal side effect of fluoxetine. Cureus 2021; 13(6): e15797.
[http://dx.doi.org/10.7759/cureus.15797] [PMID: 34306865]
[14]
Ceylan ME, Evrensel A. Venlafaxine induced akathisia: A case report. Trends Psychiatry Psychother 2016; 38(2): 117-7.
[http://dx.doi.org/10.1590/2237-6089-2015-0084] [PMID: 27409139]
[15]
Basu B, Gangopadhyay T, Dutta N, Mandal B, De S, Mondal S. A case of akathisia induced by escitalopram: case report & review of literature. Curr Drug Saf 2014; 9(1): 56-9.
[http://dx.doi.org/10.2174/157488630901140224104651] [PMID: 24568368]
[16]
Koliscak LP, Makela EH. Selective serotonin reuptake inhibitor-induced akathisia. J Am Pharm Assoc (Wash DC) 2009; 49(2): e28-38.
[http://dx.doi.org/10.1331/JAPhA.2009.08083] [PMID: 19289334]
[17]
Gulsun M, Doruk A. Mirtazapine-Induced Akathisia 2008; 28(4): 452-77.
[18]
Revet A, Montastruc F, Roussin A, Raynaud JP, Lapeyre-Mestre M, Nguyen TTH. Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database. BMC Psychiatry 2020; 20(1): 308.
[http://dx.doi.org/10.1186/s12888-020-02711-z] [PMID: 32546134]
[19]
Eisenhauer G, Jermain DM. Fluoxetine and tics in an adolescent. Ann Pharmacother 1993; 27(6): 725-6.
[http://dx.doi.org/10.1177/106002809302700610] [PMID: 8329792]
[20]
Altindag A, Yanik M, Asoglu M. The emergence of tics during escitalopram and sertraline treatment. Int Clin Psychopharmacol 2005; 20(3): 177-8.
[http://dx.doi.org/10.1097/00004850-200505000-00010] [PMID: 15812270]
[21]
Rua A, Damásio J. Tics induced by sertraline: Case report and literature review. Mov Disord Clin Pract (Hoboken) 2014; 1(3): 243-4.
[http://dx.doi.org/10.1002/mdc3.12044] [PMID: 30713857]
[22]
Gupta D, Bhardwaj A, Prakash R, Jose N. Fluvoxamine-induced tics: A rare phenomenon. Arch Med Health Sci 2022; 10(2): 274-6.
[23]
Parraga HC, Cochran MK. Emergence of motor and vocal tics during imipramine administration in two children. J Child Adolesc Psychopharmacol 1992; 2(3): 227-34.
[http://dx.doi.org/10.1089/cap.1992.2.227] [PMID: 19630634]
[24]
Fennig S, Naisberg Fennig S, Pato M, Weiztman A. Emergence of symptoms of Tourette’s syndrome during fluvoxamine treatment of obsessive compulsive disorder. Br J Psychiatry 1994; 164(6): 839-41.
[http://dx.doi.org/10.1192/bjp.164.6.839]
[25]
Kayhan F, Uguz F, Kayhan A, Toktaş Fİ. Bupropion XL-induced motor and vocal tics. Clin Neuropharmacol 2014; 37(6): 192-3.
[http://dx.doi.org/10.1097/WNF.0000000000000056] [PMID: 25384079]
[26]
Brown K, Glen S, White T. Low serum iron status and akathisia. Lancet 1987; 329(8544): 1234-6.
[http://dx.doi.org/10.1016/S0140-6736(87)92687-0] [PMID: 2884371]
[27]
Lane RM. SSRI-Induced extrapyramidal side-effects and akathisia: Implications for treatment. J Psychopharmacol 1998; 12(2): 192-214.
[http://dx.doi.org/10.1177/026988119801200212] [PMID: 9694033]
[28]
Musco S, McAllister V, Caudle I. Dopamine-receptor blocking agent-associated akathisia: A summary of current understanding and proposal for a rational approach to treatment. Ther Adv Psychopharmacol 2020; 10.
[http://dx.doi.org/10.1177/2045125320937575] [PMID: 32922732]
[29]
Markoula S, Konitsiotis S, Chatzistefanidis D, Lagos G, Kyritsis AP. Akathisia induced by mirtazapine after 20 years of continuous treatment. Clin Neuropharmacol 2010; 33(1): 50-1.
[http://dx.doi.org/10.1097/WNF.0b013e3181bf213b] [PMID: 20124786]
[30]
Yeragani VK, Pohl R, Balon R, Kulkarni A, Keshavan M. Low serum iron levels and tricyclic antidepressant-induced jitteriness. J Clin Psychopharmacol 1989; 9(6): 447-8.
[http://dx.doi.org/10.1097/00004714-198912000-00021] [PMID: 2592591]
[31]
Schoretsanitis G, Nikolakopoulou A, Guinart D, Correll CU, Kane JM. Iron homeostasis alterations and risk for akathisia in patients treated with antipsychotics: A systematic review and meta-analysis of cross-sectional studies. Eur Neuropsychopharmacol 2020; 35: 1-11.
[http://dx.doi.org/10.1016/j.euroneuro.2020.04.001] [PMID: 32444336]
[32]
Kim J, Wessling-Resnick M. Iron and mechanisms of emotional behavior. J Nutr Biochem 2014; 25(11): 1101-7.
[http://dx.doi.org/10.1016/j.jnutbio.2014.07.003] [PMID: 25154570]
[33]
Mahadea D, Adamczewska E, Ratajczak AE, Rychter AM, Zawada A, Eder P, et al. Iron deficiency anemia in inflammatory bowel diseases — a narrative review. Nutrients 2021; 13(11): 4008.
[34]
Diagnostic and Statistical Manual of Mental Disorders. (Fifth Edition, Text Revision.), American Psychiatric Association 2022.
[35]
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2): 239-45.
[http://dx.doi.org/10.1038/clpt.1981.154] [PMID: 7249508]
[36]
Lee MS, Lee HY, Kim SH. Relapse of tic symptoms in a patient diagnosed with obsessive-compulsive disorder and treated with high-dose paroxetine. J Child Adolesc Psychopharmacol 2008; 18(3): 305-6.
[http://dx.doi.org/10.1089/cap.2007.0143] [PMID: 18582189]
[37]
Moshe K, Iulian I, Seth K, Eli L, Joseph Z. Clomipramine-induced tourettism in obsessive-compulsive disorder: clinical and theoretical implications. Clin Neuropharmacol 1994; 17(4): 338-43.
[http://dx.doi.org/10.1097/00002826-199408000-00005] [PMID: 9316681]
[38]
Liu Y, Tai Y, Cheng Y. Tics induced by mirtazapine in a young patient. Taiwan J Psychiatry 2014; 28(3): 186-7.